Sandoz Agrees To Shelve Plans For Generic Zetia
Generic-drug maker Sandoz Inc. on Monday agreed not to make, sell or distribute a version of Merck & Co. Inc.'s anti-cholesterol drug Zetia until 2017, putting to rest Merck's patent infringement...To view the full article, register now.
Already a subscriber? Click here to view full article